Keytruda is projected to be the top-ranked drug worldwide based on sales in 2024, with more than 27 billion U.S. dollars. This statistic displays the expected top drugs in 2024 based on sales projections as of December 2023. Due to the patent expiration in the U.S., AbbVie's blockbust...
A TTO analysis was conducted for the 26 drugs that generated risk signals, revealing that all drugs exhibited an early failure type. The median TTO for orlistat was 3 days, the shortest of all the drugs, while the median TTO for clozapine was 1,065 days, the longest ...
The FDA approved 26 new Teva generics in 2021, with 200 awaiting approval, including 69 on a tentative basis, the company said in its SEC filing. "Our generic drugs face intense competition," Teva wrote in the 10-K report. "Prices of generic drugs may, and often do, decline, sometimes...
Pharmaceuticals and Diagnostics, with over 40 medicines in the Pharmaceuticals vertical. The Pharmaceuticals Division contributed to more than 75% of the overall annual revenue (majorly contributed by Oncology and Immunology drugs) while the Diagnostics Division contributed to the remaining share of ...
Illegal drugs are expected to be one of the biggest threats to national security in 2024, according to the Department of Homeland Security's annual threat study.
NO. 1 KeytrudaCompany: Merck & Co.2024 worldwide sales forecast: $27.19 billion In September 2014, the U.S. Food and Drug Administration (FDA) approved Keytruda (Pembrolizumab), a PD-1 monoclonal antibody for the treatment of cancer. For the first four years since approval, the Keytruda un...
This compilation of top pharmacist-recommended over-the-counter medicines and health products may make your next trip to the drugstore easier.
while personal care products had a market share of eight percent. Antidiabetics was the category ofprescription drugs with the highest revenue, amounting to 1.8 billion euros in 2020. In the case ofover-the-counter pharmaceuticals, sales of eye care products amounted to more than 200 million eu...
Some drugs not included in the report, such as UCB’s Neupro, appear to be inching toward generic competition. But, in a recentannual report(PDF), UCB said a trial with Viatris is scheduled for 2024, making the generic launch timing not certain. ...
表:2024年在美专利到期的十大药物 数据来源:FIERCE Pharma 1 Sprycel (达沙替尼) 适应症:慢性粒细胞白血病 研发企业:BMS 2023年美国销售额:14.5 亿美元 生物类似药上市时间:2024年9月 Sprycel(达沙替尼)是百时美施贵宝(BMS)肿瘤学主打产品之一,是一种针对癌细胞中特定蛋白质并阻止癌细胞生长的药物。